Home » Topics » BioWorld Science, Patents

BioWorld Science, Patents
RSS

Pfizer reports neuroleptics

June 7, 1996

Asahi Chem. claims sigma-receptor ligands

June 7, 1996

Compounds with high affinity for 5-HT1A and/or D2 receptors reported by E. Merck

June 7, 1996

Bristol-Myers Squibb describes compounds with melatonergic properties

June 7, 1996

CDR-grafted type III anti-CEA MAbs identified

June 7, 1996

Hoescht reports imidobisphosphonic acid derivatives

June 7, 1996

Fujisawa claims ACAT inhibitors

June 7, 1996

Indena claims colchicine derivatives

June 7, 1996

E. Merck describes immunoconjugates

June 7, 1996

Knoll describes antiarthritic and immunomodulator derivatives

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Nov. 12, 2025.
Could restricting diversity efforts stall women’s health research?
BioWorld
Recent progress in redressing the historical underfunding and neglect of women’s health could be undermined by the backlash against diversity, equity and...
Alkermes’ alixorexton hits endpoints in narcolepsy phase II
BioWorld
Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically...
Pazdur ‘optimal fit’ to lead FDA’s CDER
BioWorld
In reaching within to name 26-year FDA veteran Richard Pazdur as the next CDER director, FDA Commissioner Marty Makary likely chose the best possible person to...